RxDoctor Payments Data

Michael Musho, MD

Internal Medicine · Rockledge, PANPI 1548255912

Payments from drug & device makers

$1,257in general payments, 2019–2025

Across 81 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$460
  • Daiichi Sankyo Inc.$114
  • Amgen$111
  • AstraZeneca$95
  • Astellas Pharma US Inc$93
  • Pfizer$80
  • plus $304 from 8 others

What the payments were for

  • Food & beverage$1,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,257 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$61,090
Medicare patients
354
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate98$95,747
EliquisApixaban104$93,722
TrulicityDulaglutide42$59,475
OzempicSemaglutide29$42,473
JardianceEmpagliflozin22$30,889
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$17,390
XareltoRivaroxaban11$17,113
JanumetSitagliptin Phos/Metformin Hcl13$15,076
Breo ElliptaFluticasone/Vilanterol17$10,849
Atorvastatin Calcium624$9,091
TradjentaLinagliptin12$6,317
Simvastatin343$4,800
Levothyroxine Sodium323$4,669
Incruse ElliptaUmeclidinium Bromide13$4,318
Lisinopril429$4,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$51$110,823111 claims
PfizerEliquis, Premarin$80$97,236117 claims
Lilly USA, LLCTrulicity$75$59,47542 claims
Novo NordiskOzempic$460$42,47329 claims
GSKAnoro Ellipta, Breo Ellipta, Incruse Ellipta$19$32,55754 claims
Johnson & JohnsonXarelto$42$17,11311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Rockledge

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →